Bacil Pharma Ltd vs Gujarat Themis Biosyn Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The P/E Ratio of Bacil Pharma Ltd changed from 146.5 on March 2025 to 146.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 years The Market Cap of Bacil Pharma Ltd changed from ₹ 1.84 crore on March 2021 to ₹ 60.99 crore on March 2025 . This represents a CAGR of 101.41% over 5 yearsThe Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 years The revenue of Bacil Pharma Ltd for the Dec '25 is ₹ 0.06 crore as compare to the Sep '25 revenue of ₹ 0.05 crore. This represent the growth of 20% The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The ebitda of Bacil Pharma Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.02 crore. This represent the growth of 100% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The net profit of Bacil Pharma Ltd changed from ₹ -0.03 crore to ₹ 0.04 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The Dividend Payout of Bacil Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 years .

About Bacil Pharma Ltd

Incorporated as a private limited company in Maharashtra in May '87, Bacil Pharma (BPL) was converted into a public limited company in Oct.'90.
The main business activity of the Company is Pharmaceutical. Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs.
Domestic operations are spread across pan India.
The company has strong field force of 500 plus, spread over various States and Districts.
It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage.

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

FAQs for the comparison of Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd

Which company has a larger market capitalization, Bacil Pharma Ltd or Gujarat Themis Biosyn Ltd?

Market cap of Bacil Pharma Ltd is 81 Cr while Market cap of Gujarat Themis Biosyn Ltd is 3,963 Cr

What are the key factors driving the stock performance of Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd?

The stock performance of Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd?

As of May 4, 2026, the Bacil Pharma Ltd stock price is INR ₹56.95. On the other hand, Gujarat Themis Biosyn Ltd stock price is INR ₹363.75.

How do dividend payouts of Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd compare?

To compare the dividend payouts of Bacil Pharma Ltd and Gujarat Themis Biosyn Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.